ARTICLE | Company News
Genentech, BioNTech in personalized vaccine deal
September 21, 2016 7:00 AM UTC
The Genentech Inc. unit of Roche (SIX:ROG;OTCQX:RHHBY) and BioNTech AG (Mainz, Germany) partnered to develop and commercialize personalized mRNA-based immunotherapies that target patient neoantigens to treat a variety of cancers.
BioNTech will receive an upfront payment and near-term milestones totaling $310 million. The companies will share all development costs and potential profits equally, and BioNTech has an option to co-promote vaccines in the U.S. and other major European markets. ...